DB05958ExperimentalProtein Based Therapies
SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer. SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block...
- Primary indication
- Investigated for use/treatment in asthma, retinal disorders (unspecified), and viral infection.Curator reviewed
- Code names
- SYN-101
What you can answer from here — as of April 02, 2025
Which companies are running trials of SYN-101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account